ClinicalTrials.gg
WithdrawnNCT02677350GALENEUpdated Jan 27, 2026

AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)

A Phase 1 interventional study of Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) in Crohn's Disease, Fistulizing Crohn's Disease and Stem Cells, sponsored by Joshua M Hare. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Joshua M Hare · Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
Study is permanently closed to enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the role of allogeneic mesenchymal stem cells for treatment of perianal fistulizing Crohn disease.

Twenty (20) Crohn's disease patients with complex or multiple perianal or rectovaginal fistulas will be included and will be scheduled to undergo peri-fistula injections after meeting all inclusion/exclusion criteria's at baseline.

Following the Pilot Phase of four (4) subjects, sixteen (16) subjects are scheduled to undergo perianal injections and after meeting all inclusion/exclusion criteria's, will be evaluated at baseline.

Read the detailed description

Twenty (20) subjects will be treated with 20 million (2 x 10\^7) allogeneic MSC's total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection..

For patients with more than 6 fistula tracts, the largest of the tracts will be injected.

The first four (4) subjects that receive their initial injections will not be treated less than 5 days apart. As stated in the above response, these first four (4) patients will have an initial safety follow up period of one month prior to proceeding with the treatment of further patients.

Follow up: Clinical (CDAI, PDAI, and perianal examination +/- under anesthesia), and endoscopic ultrasound will be performed at the time of each treatment. MRI evaluation will be performed at screening, 4 weeks after the fourth treatment (week 16) and at 16 months, if fistula closure has not been achieved. Clinical evaluation will be performed at months 1, 3, 6, 12. Endoscopic ultrasound and MRI will also be performed as needed for symptomatic patients if an abscess is suspected.

Duration of Study participation: 17 Months (Follow-up visits will be at 4, 7, 10 and 16 Months post treatment.

The Allo-hMSCs will be supplied from an allogeneic human mesenchymal stem cell source manufactured by the University of Miami.

02

Conditions studied

  • Crohn's Disease
  • Fistulizing Crohn's Disease
  • Stem Cells

Browse trials for

03

In context

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Lead sponsor

Joshua M Hare is the lead sponsor of 15 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written .
  2. Male and Female subjects ≥ 18 years of age at the time of signing the Informed Consent Form.
  3. Subjects with Fistulizing Crohn´s disease with complex perianal fistula, multiple perianal fistulas, or rectovaginal fistula(s). The complex perianal fistula is defined as a trans-sphincteric, supra-sphincteric or an extra-sphincteric tract. Patients with multiple fistulas, "horseshoe" fistula," or any fistula with fecal incontinence as a result of the Crohn's disease itself or because of previous anal fistula surgery that cannot have more surgery are also eligible.
  4. If drainage of abscess is needed, it should be done 2 or more weeks prior to onset of therapy.
  5. Have had Crohn's Disease (CD) diagnosed at least 6 months prior to enrollment based on clinical, endoscopic, anatomic/pathologic and/or radiologic criteria.
  6. Have a CDAI score \<350.
  7. During the course of the subject's Crohn's disease (CD), subject must have received anti-Tumor Necrosis Factor (TNF) agents or immunomodulators which did not heal the CD fistulas. If anti-TNFs or immunomodulators are or led to adverse events, patients must have failed conservative therapy with antibiotics, or setons, or surgical intervention.
  8. Subject who are currently receiving anti-TNFs, antibiotics, 5-aminosalicylic acid, azathioprine, 6-mercaptopurine, methotrexate, prednisone, or any similar drugs at the time of enrollment as long as the following criteria are met:

    1. The patient must have been on the anti-TNF for at least 4 months
    2. The dose of 5-aminosalicylic acid (5-ASA) must have been stable for at least 4 weeks prior to enrollment.
    3. The dose of must have been stable for at least 2 weeks prior to enrollment.
    4. The dose of antibiotics must have been stable for at least 2 weeks prior to enrollment.
    5. The dose of immunomodulators (for example, azathioprine, 6-mercaptopurine, or methotrexate) must have been stable for at least 8 weeks prior to enrollment and the subject on therapy for at least three months prior to enrollment
  9. Patient is, in the investigator's opinion, willing and able to comply with the protocol requirements

Exclusion criteria

Exclusion Criteria:

In order to participate in this study, a patient Must Not:

  1. Have a known, serious radiographic contrast allergy (gadolinium in particular)
  2. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or values \< 100,000/ul without another explanation.
  3. Have liver dysfunction, as evidenced by enzymes ( and ALT) greater than three times the Upper limit normal.
  4. Have a coagulopathy ( (INR) > 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \< 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment.
  5. Bone marrow dysfunction, as evidenced by a 20% or more deviation from normal hematocrit, white blood cell count or platelet values without another explanation.
  6. Be an organ transplant recipient.
  7. Clinical history of within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
  8. Non-cardiac condition that limits lifespan to \< 1 year.
  9. Patients with a highly active luminal CD, i.e., if they meet any of the following criteria: - Presence of severe proctitis (prominent friability, spontaneous bleeding, multiple erosions, deep ulcers) or very active luminal disease that requires immediate treatment, revealed by colonoscopy.
  10. Have anal dysplasia
  11. Patients that have received radiation to the pelvic/perianal area.
  12. Presence of abscess or other collections not drained (revealed by baseline radiologic study).
  13. Presence of setons unless they are removed before treatment beginning.
  14. Rectal and/ or anal stenosis that cannot be adequately evaluated for dysplasia by Examination under anesthesia or endoscopy.
  15. Need surgery in the perianal region for reasons other than fistulas at inclusion or within 16 weeks after treatment administration.
  16. Had a stable dose of an anti-TNF agent within the past 8 weeks before the cell treatment administration.
  17. Taking tacrolimus or cyclosporine and not on a stable maintenance dose for 2 weeks before the start of scheduled interventions.
  18. Have a history of alcohol or other addictive substances abuse within 6 months before inclusion.
  19. Severe uncontrolled diseases (chronic renal failure, cardiovascular, pulmonary or any systemic disease).
  20. Any type of medical or psychiatric disease which are considered as exclusion criteria, in the investigator's opinion.
  21. Subjects with congenital or acquired immunodeficiency.
  22. Positive serology for (HIV), Virus (HBV) or Virus (HCV), Human papillomavirus (HPV) or Herpes Virus.
  23. Had major surgery or serious traumatism within 6 weeks of enrollment.
  24. Impossibility of doing an radiological exploration (reaction to contrast material, pacemakers, claustrophobia, etc.)
  25. Have to dimethyl sulfoxide (DMSO)
  26. Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial.
  27. Be a female who is pregnant, nursing, or of while not practicing effective methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pilot

    Twenty (20) subjects will be treated with 20 million (2 x 10\^7) Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs) total divided into 10 injections of 2 million cells/cm of tract in 0.5 ml volume (for total volume of 5 ml per visit) at 4 week intervals for a maximum of 4 treatment sessions based on the discretion of the endoscopist at the time of injection.

    Drug: Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluation of treatment emergent adverse events from the bone marrow-derived allogeneic mesenchymal stem cells implant

    Evaluation of treatment emergent adverse events based on viability, safety and tolerance of the bone marrow-derived allogeneic mesenchymal stem cells implant (MSCs) in fistulizing Crohn's Disease patients, defined as: * Treatment emergent adverse event (AE) rates, infections, hospitalizations or surgical interventions. * Physical examination * Vital signs * Laboratory tests (biochemistry, hematology, urinalysis)

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

Secondary outcomes

  1. Clinically: to assess changes in the Crohn's Disease Activity Index (CDAI), the Perianal Disease Activity Index (PDAI).

    To monitor the number of draining fistulas, fistula healing efficiency, relapse rate among patients who achieved treatment success and amount local inflammation: Complete closure will be defined as absence of discharge and absence of collections of ≥2 cm directly related to the treated fistulas tracts as assessed by perianal examination. Partial closure will be defined as a reduction in \>50% draining fistulas or no discharge on finger compression.

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

  2. Endoscopic assessment of rectum using a limited simplified endoscopic activity score for Crohn's disease (SES-CD) to evaluate extent and severity of ulcers.

    Endoscopic ultrasound and Examination under anesthesia to evaluate baseline fistula state and during each intervention to assess tract closure and abscesses. Remission will be defined as healing of rectal ulcers and/or closure of fistula tracts by endoscopic ultrasonography.

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

  3. Radiologic assessment using MRI

    to examine number of tracts, inflammation in tracts, and extent of fibrosis or regenerative tissue via MRI assessment. Radiologic remission will be defined as substitution of tracts with fibrosis or regenerative tissue.

    Time frame: Baseline, Month 4, and 16 months only if fistula closure has not been achieved at month 4

  4. Evaluate symptomatic patients.

    Endoscopic ultrasound and MRI will be used to evaluate symptomatic patients.

    Time frame: Month 4 and Month 16

  5. Evaluate the effect of local treatment with allogeneic bmMSCs using the short Inflammatory Bowel Disease Questionnaire (sIBDQ)

    To evaluate the effect of local treatment with allogeneic bmMSCs on the quality of life of patients with fistulizing CD using the short Inflammatory Bowel Disease Questionnaire (sIBDQ)

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

  6. Evaluate the effect of local treatment with allogeneic bmMSCs using the Short Form (SF)-36 score

    To evaluate the effect of local treatment with allogeneic bmMSCs on the quality of life of patients with fistulizing CD using the Short Form (SF)-36 score

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

  7. C-reactive protein (CRP)

    To summarize the changes from baseline compared to 12 weeks in serum C-reactive protein

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

  8. Major Adverse Events

    • Incidence of the Major Adverse Events endpoint, defined as the composite incidence of (1) death (2) hospitalization for worsening fistulizing disease (3) or infection caused by the intervention.

    Time frame: At each intervention and 7, 10, and 16 months after last intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2019; primary completion for Dec 2025, 72 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2016
First posted
Feb 9, 2016
StartEst.
Dec 1, 2019
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02677350
Lead sponsor
Joshua M Hare
Responsible party
Joshua M Hare (Sponsor, University of Miami) — Sponsor-investigator
First posted
Feb 9, 2016
Start date
Dec 1, 2019 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 27, 2026

Study contacts

David Kerman, MD
principal investigator · ISCI / University of Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Laromestrocel

Start the discussion